The expression of B cell associated and restricted antigens on tumor cells isolated from 138 patients with non-T cell acute lymphoblastic leukemia (non-T cell ALL) was investigated by flow cytometric analysis by means of a panel of monoclonal antibodies. Tumor cells from these patients could be assigned to one of four subgroups: human leukocyte antigen-DRrelated Ia-like antigens (Ia) alone (4%, stage I); IaB4 (14%, stage II); IaB4CALLA (33%, stage III); and IaB4CALLAB1 (49%, stage IV). The expression of B cell-restricted antigens (B4 and B1) and rearrangements of Ig heavy chain genes provided strong evidence for the B cell lineage of stages II, III, and IV tumors. The lineage of the Ia alone group is still unknown. The B4 antigen was expressed on approximately 95% of all non-T cell ALLs tested, and given its absence on T cell and myeloid tumors, it appears to be an exceptional marker to define cells of B lineage. The demonstration that Ia alone, IaB4, IaB4CALLA, and IaB4CALLAB1 positive cells can be readily identified by dual fluorescence analysis in normal fetal and adult bone marrow provided critical support for the view that these leukemic pre-B cell phenotypes were representative of the stages of normal pre-B cell differentiation. It was interesting that the IaB4+ cell was more frequently identified in fetal bone marrow than in adult marrow, […] (B4 and B,) and rearrangements of Ig heavy chain genes provided strong evidence for the B cell lineage of stages II, III, and IV tumors. The lineage of the Ia alone group is still unknown. The B4 antigen was expressed on -95% of all non-T cell ALLs tested, and given its absence on T cell and myeloid tumors, it appears to be an exceptional marker to define cells of B lineage.
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The demonstration that Ia alone, IaB4, IaB4CALLA, and IaB4CALLAB, positive cells can be readily identified by dual fluorescence analysis in normal fetal and adult bone marrow provided critical support for the view that these leukemic pre-B cell phenotypes were representative of the stages of normal pre-B cell differentiation. It was interesting that the IaB4+ cell was more frequently identified in fetal bone marrow than in adult marrow, whereas the predominant cell found in adult marrow expressed
Introduction
Increasing evidence based upon immunologic cell-surface phenotype and Ig gene rearrangements supports the idea that leukemic cells from patients with non-T cell acute lymphoblastic leukemia (non-T cell ALL)' appear to be the neoplastic counterparts of normal pre-B cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Initially, the cell-surface expression of B lineage-associated determinants including the human leukocyte antigen-DR-related Ia-like antigens (Ia) and the common acute lymphoblastic leukemia antigen (CALLA) suggested that these tumors might be of B cell origin (1) (2) (3) .
Subsequently, it was observed that -15% of these tumors contained cytoplasmic ,u-heavy chains (c,u) (4-6) and 50% expressed the B, antigen, a B cell-restricted cell-surface determinant (7) . Both sets ofobservations support the view that non-T cell ALLs are pre-B cells and suggest the possibility that at least half of these tumors correspond to or precede the conventional c,u positive pre-B cell. Several lines of evidence support the hypothesis that the other 50% of non-T cell ALLs are also derived from early pre-B cells. Thus, the expression of cell surface and cytoplasmic B cell-restricted markers provided evidence that these tumors were derived from early human pre-B cells.
Recent analysis ofIg gene rearrangements has demonstrated that most, if not all, non-T cell ALLs and lymphoid chronic myeloblastic leukemia (CML)-blast crises were of B cell origin (10) (11) (12) (13) . However, several groups have demonstrated that occasional T cell and myeloid tumors, both in murine and human systems, may also display heavy-chain Ig gene rearrangements (1 1, 13-18). In contrast, light-chain rearrangements have thus far been restricted to cells of B cell origin. This indicates that several parameters will be necessary to characterize fully the lineage and stage of differentiation of an individual tumor.
In the present report, we have immunologically characterized tumor cells isolated from 138 patients with non-T cell ALL.
We show that tumor cells isolated from these patients can be subdivided into four phenotypically defined subgroups based upon the expression or coexpression of B cell-associated antigen Ia, and of CALLA and B cell-restricted antigens B4 and Bl. In the studies described below, we demonstrate that four leukemic subgroups correspond to distinct stages of normal pre-B cell differentiation. Moreover, we will demonstrate that leukemic pre-B cell subgroups appear to correlate with the distribution of pre-B cell subsets in normal fetal and adult bone marrow.
Methods
Patients and samplepreparations. All patients in this study were evaluated at the Dana Farber Cancer Institute, The Children's Hospital Medical Hospital, the Brigham and Women's Hospital, or the Beth Israel Hospital (all in Boston). The diagnosis of non-T cell ALL was made on the basis of standard morphologic and cytochemical criteria (19, 20) and the lack of reactivity with anti-Ig (IgM, IgG, K, and X), anti-T cell antibodies (anti-T1, T3, T4, T6, T8, and T,1) (21) and antimyeloid antibodies (anti-MY7, MY8, MY9, and Mo,) (22) (23) (24) . Heparinized peripheral blood or bone marrow was collected from leukemic patients before the administration of chemotherapeutic agents or blood products. Mononuclear cells were separated from these specimens by Ficoll-Hypaque density gradient centrifugation as previously described (25) . For (27) . Monoclonal anti-B4 has been previously shown to define a 40/80 kD-glycoprotein, which is B cell specific within the hematopoietic system and is not expressed on normal T cells, myeloid cells, erythrocytes, or platelets. The B4 antigen is found on all normal and malignant B lymphocytes, excluding the plasma cell. The B4 antigen has not been demonstrated on any T cell (n = 37) or myeloid tumor (n = 172) and is therefore considered to be a B cellrestricted antigen. CALLA is identified by the J5 monoclonal antibody (28) . Js precipitates a 100,000 kD glycoprotein, which is expressed on leukemic cells of 80% of patients with non-T cell ALL and 30% of patients with CML in lymphoid blast crisis. CALLA is also found on '20% of patients with T cell ALL, 40% of patients with T cell lymphoblastic lymphoma, and on the tumor cells of most patients with Burkitt's lymphoma and nodular, poorly differentiated lymphocytic lymphoma (29) . Moreover, it has been shown that CALLA+ cells can be isolated from normal fetal hematopoietic tissues and adult bone marrow and that varying percentages of these cells coexpress the B, antigen, cbs, and terminal deoxytransferase (30) . CALLA is therefore also considered to be associated with, but not restricted to, B cells.
Monoclonal anti-B, has been previously shown to be B cell specific within the hematopoietic system and is expressed on all B cells, both normal and malignant, except for the terminally differentiated plasma cells (7, (31) (32) (33) . This monoclonal antibody defines a 35-kD nonglycosylated phosphorylated protein (34) . The B, antigen has not been demonstrated on any myeloid (n = 220) or T cell tumors (n = 57).
Fetal tissues. Fetal tissues were obtained within 1 h of prostaglandininduced therapeutic abortion. All patients who underwent therapeutic abortion had last menstrual periods and diagnostic ultrasound imaging that suggested that the fetal age was less than 24 wk. To standardize comparison of gestational age, age determination postmortem was determined by crown-rump length and fetal foot length (35 Ig-gene analysis. Detailed techniques have been previously described (1 1). In brief, high molecular weight DNA prepared from leukemic cells was digested with the BamHI and EcoRI restriction endonuclease, size fractionated by agarose gel electrophoresis, and transferred onto nitrocellulose paper. The nitrocellulose blots were hybridized with nick-translated 32P-DNA probes of human Ig genes that could detect germ line and rearranged alleles. The joining heavy probe was 2.4-kilobase (kb) Sau 3a fragment, the constant K-probe was a 2.5-kb EcoRI fragment, and the constant A-probe was a 0.8-kb G12-EcoRI constant Xl-probe fragment. Such blots were washed at the appropriate stringencies and were visualized on autoradiograms.
Immune rosette depletion. In order to isolate the normal pre-B cell counterparts of non-T cell ALL, immune rosette depletion of fetal and adult bone marrow was undertaken by use of sheep erythrocytes bound to rabbit anti-mouse Ig as previously described (40, 41) . Monoclonal antibodies used to deplete fetal and adult bone marrows of T cells, and of erythroid and myeloid precursors included anti-T3, anti-T,,, anti-Tg, anti-Mo,, and anti-Mo2, respectively. Antibodies were first incubated with either fetal or adult bone marrow cells at excess concentrations for 30 min at 4°C and then washed. These antibody-labeled cells were then incubated with rabbit anti-mouse Ig conjugated sheep erythrocytes. After a 10-min incubation at room temperature and a 10-min centrifugation (800 rpm at 4°C), rosetting was done for 1 h at room temperature. The sheep erythrocyte pellet was gently resuspended and the mixture was subjected to Ficoll-Hypaque density sedimentation to separate the rosette negative monolayer from the positive pellet. These rosette negative cells, which are enriched for B lineage cells and which were used in a dual fluorescent assay ofthe expression and/or coexpression of the B cell associated and restricted antigens.
Statistical methods. Deviation from independence in the data of Table III was assessed by treating it in a contingency table. This produced a value that is distributed as a chi-square (which, for an r X c table, has (r -1Xc -1) degrees of freedom). Individual elements were further tested by the construction of 2 x 2 tables from elements of the larger table, as described in the text, and by the application Fischer's exact test (42, 43) .
Results
Subgroups of non-T cell ALL based upon the coexpression of the Ia, B4, CALLA, and B, antigens. Tumor cells from 138 patients with non-T cell ALL were evaluated for reactivity with a panel of B cell-associated (anti-Ia and anti-CALLA) and B cell-restricted (anti-B4 and anti-B,) monoclonal antibodies. Four subgroups of non-T cell ALL could be identified by the expression or coexpression of Ia, B4, CALLA, and Bl. As seen in Table I , tumor cells from all patients studied expressed the Ia antigen, more than two-thirds expressed CALLA, and approximately one-half expressed B,. The first subgroup (Ia alone), contained only 5 of the 138 patients tested (stage I) (data for all subgroups, Fig. 1 and Table I ). The second subgroup (20 (Table II) . Similarly, all four stage IV (IaB4CALLABI) ALLs had rearranged heavy-chain genes, and (IaB4CALLA) 3 (17) 38 (42) 2 (20) 3 (17) IV (IaB4CALLABI) 4 (22) In contrast to the fetal bone marrow, the B cell enriched immune rosette negative fraction isolated from adult bone marrows demonstrates a different pattern ofB cell antigen expression. In the adult bone marrow there are significantly fewer cells of B lineage (Table IV) . All B4+ cells coexpress Ia and approximately three-quarters express B4 and CALLA (Tables IV and  V) . The overwhelming majority of the CALLA positives coexpress Ia, B4, and B,. When one examines the B, positive cells in the adult bone marrow cells one sees a distinct difference from the fetal marrow (Tables IV and V) . Although the B, positive cells uniformly express Ia and B4, only two-thirds coexpress CALLA; this suggests that an Ia+B4+CALLA-B,+ cell exists in adult bone marrow. Moreover, these Ia+B4 +CALLA-B,+ cells did not appear to be mature B cells from contaminating peripheral blood, since only 10% of these cells expressed surface Ig. These observations suggest that the four subpopulations seen in non-T cell ALL are seen in adult bone marrow but that fewer total pre-B cells exist in adult bone marrow and that an additional population of Ia+B4 +CALLA-B,+ mature pre-B cells can be demonstrated.
Discussion
In the present report, 138 patients with non-T cell ALL were characterized by the use of a panel of monoclonal antibodies defining B cell-associated and B cell-restricted antigens. By their differential expression of the B cell-associated antigens, Ia and CALLA, and the B cell-restricted antigens, B4 and B,, four phenotypically defined subgroups of non-T cell ALL could be defined. These are Ia alone (stage I, 4%); IaB4 (stage II, 14%); IaB4CALLA (stage III, 33%); and IaB4CALLAB, (stage IV, 49%). These four phenotypically defined subgroups have provided us with both a model to study the biological and clinical heterogeneity of non-T cell ALL and a framework to identify and isolate phenotypically identical normal stages of pre-B cell differentiation.
Although there has been significant phenotypic and genetic evidence to support the idea that non-T cell ALLs are of B cell-derived neoplasms (10-13), the observation that virtually 100% of non-T cell ALLs demonstrate Ig heavy-chain rearrangements has provided compelling evidence to support this conclusion. The finding that occasional T cell ALLs, Sezary cell syndrome, AML and a number of murine T cell lymphomas also demonstrate Ig heavy-chain rearrangement reveals that heavy-chain rearrangement is not restricted solely to cells of B lineage (1 1, 13-18) . To date, light-chain gene rearrangements have been restricted to cells of B development, but only 40% of non-T cell ALLs demonstrate light-chain recombinations (1 1). Thus, Ig-gene rearrangements are not sufficient to assign non-T ALLs to the B lineage. We propose that for non-T cell ALLs with rearrangements of heavy-chain alone, the B4 antigen provides an important independent parameter with which to It was very interesting that the distribution of these phenotypically defined subgroups of non-T cell ALL appeared to cluster according to the age of the patient at diagnosis. Most of the patients with the stage II subgroup of non-T cell ALL were children less than 2 yr old, whereas the adult non-T cell ALLs primarily expressed the stage IV phenotype. The apparent differences in subgroup frequency between young children and adults may be related to the distribution of pre-B cells in fetal and adult bone marrow. Whereas stages II, III, and IV positive cells could be identified in both fetal and adult bone marrow, it was clear that the fetal bone marrow contains a greater percentage ofstage IT positive cells than adult marrow. Furthermore, the adult marrow contained predominantly stage IV positive cells. The observation that for each age cluster the predominant leukemic pre-B cell subtype corresponds to the predominant normal pre-B cell counterpart in fetal and adult bone marrow might suggest that the neoplastic events are not restricted to a single stage of pre-B cell differentiation but randomly affect all stages of pre-B cell differentiation.
